Lance R. McMahon, Ph.D., serves as the Executive Vice President for Research and Innovation at Texas Tech University Health Sciences Center. In his position, Dr. McMahon will serve as chair of the Research Council. Additionally, he has a faculty appointment in the Jerry H. Hodge School of Pharmacy. Dr. Dharmendra Kumar Khatri is an Associate Professor in the Department of Pharmacology, NIMS Institute of Pharmacy at NIMS University Rajasthan, Jaipur, India. Dr. Balachandar Vellingiri currently is investigating various neurological diseases and developing human induced pluripotent stem cells (HiPSCs). Exploring the cutting-edge molecular, cellular, and translational neuroscience approaches, he aims to unravel disease mechanisms, identify therapeutic targets, and develop innovative interventions to slow or reverse neurological diseases. His expertise is on several techniques such as molecular cytogenetics, pathway analysis, and techniques in developing HiPSCs and Brain organoids, especially for neurological diseases.

• Section I: Fundamentals of Epigenetics and miRNA in Neurodegeneration1. Introduction to Epigenetics and miRNA in neurodegenerative diseases2. Epigenetic Mechanisms in the Nervous System3. miRNA Biogenesis and Function in Brain HealthSection II: Epigenetics and miRNA in Specific Neurodegenerative Disorders4. Alzheimer’s Disease: Epigenetic and miRNA Contributions5. Parkinson’s Disease: The Role of Epigenetic Modifications6. Huntington’s Disease: Epigenetic and Post-Transcriptional Control7. Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD): Molecular Crosstalk8. Multiple Sclerosis: Epigenetic and miRNA Influence on NeuroinflammationSection III: Translational and Clinical Applications9. Epigenetic Biomarkers in Neurodegenerative Diseases10. miRNA-Based Therapeutics: Challenges and Opportunities11. Pharmacological and Nutritional Epigenetics in Neuroprotection12. Gene Editing and Epigenetic Engineering Approaches13. Artificial Intelligence and Computational Epigenomics in NeurodegenerationSection IV: Future Perspectives and Ethical Considerations14. Personalized Medicine in Neurodegenerative Diseases: The Role of Epigenetics and miRNA15. Ethical, Legal, and Social Implications of Epigenetic and miRNA-Based Therapies

Lance R. McMahon, Ph.D., serves as the Executive Vice President for Research and Innovation at Texas Tech University Health Sciences Center. In his position, Dr. McMahon will serve as chair of the Research Council. Additionally, he has a faculty appointment in the Jerry H. Hodge School of Pharmacy. Dr. Dharmendra Kumar Khatri is an Associate Professor in the Department of Pharmacology, NIMS Institute of Pharmacy at NIMS University Rajasthan, Jaipur, India. Dr. Balachandar Vellingiri currently is investigating various neurological diseases and developing human induced pluripotent stem cells (HiPSCs). Exploring the cutting-edge molecular, cellular, and translational neuroscience approaches, he aims to unravel disease mechanisms, identify therapeutic targets, and develop innovative interventions to slow or reverse neurological diseases. His expertise is on several techniques such as molecular cytogenetics, pathway analysis, and techniques in developing HiPSCs and Brain organoids, especially for neurological diseases.

• Section I: Fundamentals of Epigenetics and miRNA in Neurodegeneration1. Introduction to Epigenetics and miRNA in neurodegenerative diseases2. Epigenetic Mechanisms in the Nervous System3. miRNA Biogenesis and Function in Brain HealthSection II: Epigenetics and miRNA in Specific Neurodegenerative Disorders4. Alzheimer’s Disease: Epigenetic and miRNA Contributions5. Parkinson’s Disease: The Role of Epigenetic Modifications6. Huntington’s Disease: Epigenetic and Post-Transcriptional Control7. Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD): Molecular Crosstalk8. Multiple Sclerosis: Epigenetic and miRNA Influence on NeuroinflammationSection III: Translational and Clinical Applications9. Epigenetic Biomarkers in Neurodegenerative Diseases10. miRNA-Based Therapeutics: Challenges and Opportunities11. Pharmacological and Nutritional Epigenetics in Neuroprotection12. Gene Editing and Epigenetic Engineering Approaches13. Artificial Intelligence and Computational Epigenomics in NeurodegenerationSection IV: Future Perspectives and Ethical Considerations14. Personalized Medicine in Neurodegenerative Diseases: The Role of Epigenetics and miRNA15. Ethical, Legal, and Social Implications of Epigenetic and miRNA-Based Therapies

Lance R. McMahon, Ph.D., serves as the Executive Vice President for Research and Innovation at Texas Tech University Health Sciences Center. In his position, Dr. McMahon will serve as chair of the Research Council. Additionally, he has a faculty appointment in the Jerry H. Hodge School of Pharmacy. Dr. Dharmendra Kumar Khatri is an Associate Professor in the Department of Pharmacology, NIMS Institute of Pharmacy at NIMS University Rajasthan, Jaipur, India. Dr. Balachandar Vellingiri currently is investigating various neurological diseases and developing human induced pluripotent stem cells (HiPSCs). Exploring the cutting-edge molecular, cellular, and translational neuroscience approaches, he aims to unravel disease mechanisms, identify therapeutic targets, and develop innovative interventions to slow or reverse neurological diseases. His expertise is on several techniques such as molecular cytogenetics, pathway analysis, and techniques in developing HiPSCs and Brain organoids, especially for neurological diseases.

• Section I: Fundamentals of Epigenetics and miRNA in Neurodegeneration1. Introduction to Epigenetics and miRNA in neurodegenerative diseases2. Epigenetic Mechanisms in the Nervous System3. miRNA Biogenesis and Function in Brain HealthSection II: Epigenetics and miRNA in Specific Neurodegenerative Disorders4. Alzheimer’s Disease: Epigenetic and miRNA Contributions5. Parkinson’s Disease: The Role of Epigenetic Modifications6. Huntington’s Disease: Epigenetic and Post-Transcriptional Control7. Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD): Molecular Crosstalk8. Multiple Sclerosis: Epigenetic and miRNA Influence on NeuroinflammationSection III: Translational and Clinical Applications9. Epigenetic Biomarkers in Neurodegenerative Diseases10. miRNA-Based Therapeutics: Challenges and Opportunities11. Pharmacological and Nutritional Epigenetics in Neuroprotection12. Gene Editing and Epigenetic Engineering Approaches13. Artificial Intelligence and Computational Epigenomics in NeurodegenerationSection IV: Future Perspectives and Ethical Considerations14. Personalized Medicine in Neurodegenerative Diseases: The Role of Epigenetics and miRNA15. Ethical, Legal, and Social Implications of Epigenetic and miRNA-Based Therapies